The safety and adverse event profile of favipiravir in the treatment of COVID-19 patients, Turkey
Introduction: Favipiravir (FVP) is an antiviral and used to treat COVID-19. We aimed to document the safety and adverse events associated with FVP on the outcome of COVID-19 treatment. Methodology: The study included 225 adult patients with moderate COVID-19 infection (World Health Organization s...
Saved in:
| Main Authors: | Elif Tukenmez Tigen, Buket Erturk Sengel, Beste Ozben, Hande Perk Gurun, Baran Balcan, Beliz Bilgili, Fethi Gul, Zekaver Odabasi, Volkan Korten |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2023-11-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/18041 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of favipiravir in COVID-19: A retrospective two center comparative study
by: Elif Tukenmez Tigen, et al.
Published: (2024-09-01) -
A Model for Predicting the Risk of Developing Drug-Induced Liver Injury During Therapy with Favipiravir
by: Yu. V. Shevchuk, et al.
Published: (2025-02-01) -
Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?
by: Abdullah Sayiner, et al.
Published: (2022-03-01) -
Phase I Pharmacokinetics Study of Drug for Infusion «Areplivir» (INN: Favipiravir) (LLC "PROMOMED RUS", Russia)
by: T. N. Komarov, et al.
Published: (2023-05-01) -
Protective Roles of Green Extract Zinc Oxide Nanoparticles on Monosodium Glutamate-Induced Hepatotoxicity and Nephrotoxicity in Female Rats.
by: Azheen Abdulrahman, et al.
Published: (2025-01-01)